Navigation Links
PRA International Hosts Audio Conference on CV Drug Development
Date:8/16/2010

RALEIGH, N.C., Aug. 16 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

Dr. Kirchengast will discuss ways to prevent some of the expensive failures that pharmaceutical companies experience during late-stage CV drug development. The conference will review predictive pre-clinical models, innovative proof-of-concept designs in Phase IIa, cooperation among sponsors and regulatory agencies, and simpler protocols with similar endpoints throughout Phases II and III.

PRA's therapeutic expert in CV disease, Dr. Kirchengast has 30 years of experience in CV research and development, including interactions with multiple authorities. His wide range of development experience encompasses antiarrhythmics, antithrombotics, antihypertensives, antihyperlipidemics, heart failure therapeutics, and vascularly active and cardioprotective drugs.

PRA's Scientific Affairs group consists of strategic drug development professionals with expertise in medical informatics and investigator relations as well as therapeutic expertise in cardiovascular, oncology/hematology, infectious diseases, neurosciences, pediatrics, and respiratory medicine. The group combines in-house scientific expertise with hands-on pharmaceutical industry experience, guiding the development of drugs and biologics from the late preclinical phase to the marketing stage across PRA's core therapeutic areas.

For more information about this audio conference, navigate to www.praintl.com and click on "Events." To register, email endpoints@praintl.com. The registration deadline is Monday, 23 August 2010.

About PRA International

PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dyadic International Reports 2010 Second Quarter Financial Results
2. Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010
3. Chindex International to Report First Quarter 2011 Financial Results
4. Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International
5. Airline Passenger Experience Association Teams Up With ORBIS International in Their Fight Against Avoidable Blindness
6. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
7. New Edition of Guidelines for Involving Communities in HIV Prevention Research Released at International AIDS Conference
8. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
9. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
10. Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimers Disease at International Conference on Alzheimers Disease (ICAD)
11. PRA International Hosts Audio Conference on Site and Patient Recruitment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ), a ... pathology services for evaluating risks of cancer, announced today ... 2017 from the NASDAQ Listing Qualifications notifying the Company ... the NASDAQ Stock Market to maintain a minimum closing ... letter noted that for the last 10 days from ...
(Date:1/17/2017)... 17, 2017 Tempus, a technology company ... University Hospitals Seidman Cancer Center have joined together ... data, advanced molecular analysis and clinical decision support ... healthcare providers. As part of ... transcriptomic sequencing and analysis for ovarian and triple ...
(Date:1/17/2017)... , Jan. 17, 2017  CSSi, the global ... the clinical research industry, will exhibit at the 8 ... Executives (SCOPE 2017), taking place from Tuesday, January 24 ... Miami in Miami, FL. ... proprietary technology platform, SmartStudy™ EMR, which provides a revolutionary ...
Breaking Medicine Technology:
(Date:1/17/2017)... NY (PRWEB) , ... January 17, 2017 , ... ... Magazine’s fastest-growing private companies and ranked among the top US security companies for ... of Directors. This announcement brings a year-long independent board nomination process to ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Montclair State University’s Athletic Training Education program forged a relationship built upon the ... Education Program, which is consists of both student members and certified members of ...
(Date:1/16/2017)... , ... January 16, 2017 , ... California Southern University ... has served on CalSouthern’s Board of Trustees and as a core faculty member, teaching ... has been a professor of psychology at Pepperdine University, where he earned his Doctor ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... With the ... opened on January 8 for use by sports teams and the general public. Built ... volleyball courts that can also be converted into basketball or pickleball courts. The space ...
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
Breaking Medicine News(10 mins):